Immunitybio Inc (IBRX)

$2.47 +0.08 (3.35%)
Market Cap 2.35B
Revenue (ttm) 14.75M
Net Income (ttm) -413.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,803.80%
Debt to Equity Ratio 0.00
Volume 10,620,300
Avg Vol 9,697,514
Day's Range N/A - N/A
Shares Out 984.97M
Stochastic %K 46%
Beta 0.27
Analysts Strong Sell
Price Target $10.20

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
Piquet102
Piquet102 Oct. 25 at 5:12 PM
$IBRX 298 followers only!!
0 · Reply
Stocktud
Stocktud Oct. 25 at 5:06 PM
$IBRX this is not misinformation at all! Did you read the name? This is “The Roaring Kitty 2.0” NoT “Roaring Kitty”. Please read before commenting!
0 · Reply
Stocktud
Stocktud Oct. 25 at 4:58 PM
$IBRX
0 · Reply
IVESTMYWEALTH1
IVESTMYWEALTH1 Oct. 25 at 4:57 PM
$IBRX Is this for real? I saw it on my feed today.
1 · Reply
BullriderNkg
BullriderNkg Oct. 25 at 4:35 PM
$IBRX For what it's worth, a screen shot from X.
0 · Reply
svertical1
svertical1 Oct. 25 at 4:35 PM
$IBRX $VRTX $CADL $CRSP $XBI WEALTHY Nation Price Equalization is one requirement for Voucher. https://www.breitbart.com/politics/2025/10/25/president-trump-to-investigate-european-trade-partners-for-not-paying-their-fair-share-for-american-medicines/
0 · Reply
arnolddiver
arnolddiver Oct. 25 at 4:11 PM
$IBRX stop with misinformation. This is not roaring kitty w/ 1.6m followers. I wish it was though.
1 · Reply
gogo66so
gogo66so Oct. 25 at 4:03 PM
$IBRX https://x.com/search?q=roaring%20kitty&src=typeahead_click
0 · Reply
SouthernItUp
SouthernItUp Oct. 25 at 4:02 PM
$IBRX https://x.com/alc2022/status/1981755392758542484?s=4
0 · Reply
Intime32
Intime32 Oct. 25 at 4:00 PM
$IBRX Good job stocktud on roaringkitty info he has joined the fight for the needless Suffering / Dying of Patients, He seems to be very Motivated numerous X Postings, not so much on the Capital, but on the Cancer Aspects, that carries a lot of Weight, HUGE! Thanks Again stocktud!
0 · Reply
Latest News on IBRX
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 2 days ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS PLUG RKT RXRX

ImmunityBio: A Small Bet Is Warranted

Oct 3, 2025, 1:24 PM EDT - 21 days ago

ImmunityBio: A Small Bet Is Warranted

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

Sep 11, 2025, 12:26 PM EDT - 6 weeks ago

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Aug 26, 2025, 8:30 AM EDT - 2 months ago

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Aug 19, 2025, 8:30 AM EDT - 2 months ago

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Aug 13, 2025, 8:30 AM EDT - 2 months ago

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Aug 11, 2025, 8:30 AM EDT - 2 months ago

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Aug 5, 2025, 7:00 AM EDT - 2 months ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:03 AM EDT - 3 months ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 25, 2025, 6:00 AM EDT - 3 months ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 21, 2025, 10:45 AM EDT - 3 months ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jul 7, 2025, 9:43 PM EDT - 3 months ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 12, 2025, 9:09 AM EDT - 4 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 3, 2025, 8:45 AM EDT - 5 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

Jun 2, 2025, 9:00 AM EDT - 5 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 27, 2025, 8:00 AM EDT - 5 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025, 6:30 AM EDT - 5 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 5:05 PM EDT - 6 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 9:21 AM EDT - 6 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 5, 2025, 6:30 AM EDT - 6 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29, 2025, 12:50 PM EDT - 6 months ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 28, 2025, 8:30 AM EDT - 6 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 21, 2025, 4:21 PM EDT - 6 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 15, 2025, 8:00 AM EDT - 6 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 8, 2025, 7:30 AM EDT - 7 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 7, 2025, 5:00 AM EDT - 7 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

ImmunityBio: Taking Care Of Business

Apr 3, 2025, 5:54 PM EDT - 7 months ago

ImmunityBio: Taking Care Of Business

ImmunityBio to Host Investor Day

Mar 26, 2025, 6:00 AM EDT - 7 months ago

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 13, 2025, 9:00 AM EDT - 8 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 7, 2025, 1:47 AM EST - 8 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Mar 3, 2025, 7:30 AM EST - 8 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 27, 2025, 7:10 PM EST - 8 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 19, 2025, 9:00 AM EST - 8 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 13, 2025, 3:05 PM EST - 9 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 29, 2025, 8:30 AM EST - 9 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 27, 2025, 9:00 AM EST - 9 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17, 2025, 2:05 PM EST - 10 months ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 16, 2025, 2:25 PM EST - 10 months ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 10 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 15, 2025, 5:20 PM EST - 10 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Jan 6, 2025, 9:00 AM EST - 10 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 16, 2024, 12:24 AM EST - 11 months ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 13, 2024, 2:40 PM EST - 11 months ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 12, 2024, 8:00 AM EST - 11 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 11, 2024, 7:30 AM EST - 11 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 11 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

Nov 21, 2024, 10:00 AM EST - 1 year ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Nov 19, 2024, 9:00 AM EST - 1 year ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Piquet102
Piquet102 Oct. 25 at 5:12 PM
$IBRX 298 followers only!!
0 · Reply
Stocktud
Stocktud Oct. 25 at 5:06 PM
$IBRX this is not misinformation at all! Did you read the name? This is “The Roaring Kitty 2.0” NoT “Roaring Kitty”. Please read before commenting!
0 · Reply
Stocktud
Stocktud Oct. 25 at 4:58 PM
$IBRX
0 · Reply
IVESTMYWEALTH1
IVESTMYWEALTH1 Oct. 25 at 4:57 PM
$IBRX Is this for real? I saw it on my feed today.
1 · Reply
BullriderNkg
BullriderNkg Oct. 25 at 4:35 PM
$IBRX For what it's worth, a screen shot from X.
0 · Reply
svertical1
svertical1 Oct. 25 at 4:35 PM
$IBRX $VRTX $CADL $CRSP $XBI WEALTHY Nation Price Equalization is one requirement for Voucher. https://www.breitbart.com/politics/2025/10/25/president-trump-to-investigate-european-trade-partners-for-not-paying-their-fair-share-for-american-medicines/
0 · Reply
arnolddiver
arnolddiver Oct. 25 at 4:11 PM
$IBRX stop with misinformation. This is not roaring kitty w/ 1.6m followers. I wish it was though.
1 · Reply
gogo66so
gogo66so Oct. 25 at 4:03 PM
$IBRX https://x.com/search?q=roaring%20kitty&src=typeahead_click
0 · Reply
SouthernItUp
SouthernItUp Oct. 25 at 4:02 PM
$IBRX https://x.com/alc2022/status/1981755392758542484?s=4
0 · Reply
Intime32
Intime32 Oct. 25 at 4:00 PM
$IBRX Good job stocktud on roaringkitty info he has joined the fight for the needless Suffering / Dying of Patients, He seems to be very Motivated numerous X Postings, not so much on the Capital, but on the Cancer Aspects, that carries a lot of Weight, HUGE! Thanks Again stocktud!
0 · Reply
Runmaster83
Runmaster83 Oct. 25 at 3:25 PM
$IBRX https://x.com/DrPatSoonShiong/status/1982104859345297537
1 · Reply
Intime32
Intime32 Oct. 25 at 3:18 PM
$IBRX If only every Person knew of Bioshield that has been affected by Cancer the Patients the Whole Families & the Corrupt BP Barbaric Treatments, supported by there Subsidiary FDA, for only Revenue Gain ! People need to stand up & let there voice be herd Loud & Clear, Social Media, Even Legally Protest, FDA is the most Corrupt Agency in US Government IMO! GO BIOSHIELD!
0 · Reply
Stocktud
Stocktud Oct. 25 at 3:10 PM
$IBRX If you all bros have time on the weekend, repost everything about BioShield/Anktiva all over the social media platforms. Get the words out there and save lives + make money
0 · Reply
Stocktud
Stocktud Oct. 25 at 3:05 PM
$IBRX https://x.com/lee_17601/status/1982099574027428005?s=46
0 · Reply
Stocktud
Stocktud Oct. 25 at 2:37 PM
$IBRX https://x.com/roaringkitty_69/status/1981722079650103657?s=12
1 · Reply
Intime32
Intime32 Oct. 25 at 2:29 PM
$IBRX Roaringkitty on board with Bioshield & Posting with Force on X & probably other Social Platforms He's in, GREAT! 1.6M Followers!
1 · Reply
Stocktud
Stocktud Oct. 25 at 2:16 PM
$IBRX https://x.com/roaringkitty_69/status/1981824589765468321?s=12
0 · Reply
Stocktud
Stocktud Oct. 25 at 2:13 PM
$IBRX Love and Repost please! https://x.com/roaringkitty_69/status/1981720273163354331?s=46
0 · Reply
Stocktud
Stocktud Oct. 25 at 1:38 PM
$IBRX it’s on Reddit too!
1 · Reply
Stocktud
Stocktud Oct. 25 at 1:21 PM
$IBRX LOVE and REPOST please!!!!!!!! https://x.com/roaringkitty_69/status/1981806359940046977?s=46
1 · Reply
Stocktud
Stocktud Oct. 25 at 11:55 AM
$IBRX https://x.com/roaringkitty_69/status/1981728393054797834?s=46 repost please!
4 · Reply
StellaJean
StellaJean Oct. 25 at 10:39 AM
$IBRX Antonio is the new David Din.
2 · Reply